Front. Med. Frontiers in Medicine Front. Med. 2296-858X Frontiers Media S.A. 10.3389/fmed.2022.1106530 Medicine Correction Corrigendum: Case report: Challenges in the diagnosis of a case of Mal de Meleda and a therapeutic attempt of ixekizumab and Adalimumab Dai Yuwei 1 2 3 4 5 † Zheng Xiaodong 1 2 3 4 † Zhang Qi 1 2 3 4 5 Hu Xia 1 2 3 4 5 Wang Peiguang 1 2 3 4 * Yang Sen 1 2 3 4 5 * 1Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, China 2Institute of Dermatology, Anhui Medical University, Hefei, China 3Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, Hefei, China 4Provincial Laboratory of Inflammatory and Immune Mediated Diseases, Hefei, China 5Ferry Outpatient Department, The Ferry Skin Research Institute, Hefei, China

Edited and reviewed by: Andreas Recke, University of Lübeck, Germany

 *Correspondence: Peiguang Wang ✉ wpg2370@163.com Sen Yang ✉ yang2004sen@163.com

This article was submitted to Dermatology, a section of the journal Frontiers in Medicine

†These authors have contributed equally to this work

 12 12 2022 2022 9 1106530 23 11 2022 30 11 2022 Copyright © 2022 Dai, Zheng, Zhang, Hu, Wang and Yang. 2022 Dai, Zheng, Zhang, Hu, Wang and Yang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on Case report: Challenges in the diagnosis of a case of Mal de Meleda and a therapeutic attempt of ixekizumab and Adalimumab by Dai, Y., Zheng, X., Zhang, Q., Hu, X., Wang, P., and Yang, S. (2022). Front. Med. 9:821301. doi: 10.3389/fmed.2022.821301 Mal de Meleda MDM Exomiser HPO terms Ixekizumab Adalimumab

In the published article, there was an error in the dosage of adalimumab. A correction has been made to Report, 1. This sentence previously stated:

“One month later, Adalimumab with dose of 300 mg was given subcutaneously.”

The corrected sentence appears below:

“One month later, Adalimumab with dose of 40 mg was given subcutaneously.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.